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Background: Cancer genomes harbor hundreds to thousands of somatic nonsynonymous mutations. DNA damage
and deficiency of DNA repair systems are two major forces to cause somatic mutations, marking cancer genomes
with specific somatic mutation patterns. Recently, several pan-cancer genome studies revealed more than 20
mutation signatures across multiple cancer types. However, detailed cancer-type specific mutation signatures and
their different features within (intra-) and between (inter-) cancer types remain largely unexplored.
Methods: We employed a matrix decomposition algorithm, namely Non-negative Matrix Factorization, to survey
the somatic mutations in nine major human cancers, involving a total of ~2100 genomes.
Results: Our results revealed 3-5 independent mutational signatures in each cancer, implying that a range of 3-5
predominant mutational processes likely underlie each cancer genome. Both mutagen exposure (tobacco and sun)
and changes in DNA repair systems (APOBEC family, POLE, and MLH1) were found as mutagenesis forces, each of
which marks the genome with an evident mutational signature. We studied the features of several signatures and
their combinatory patterns within and across cancers. On one hand, we found each signature may influence a
cancer genome with different influential magnitudes even in the same cancer type and the signature-specific load
reflects intra-cancer heterogeneity (e.g., the smoking-related signature in lung cancer smokers and never smokers).
On the other hand, inter-cancer heterogeneity is characterized by combinatory patterns of mutational signatures,
where no cancers share the same signature profile, even between two lung cancer subtypes (lung adenocarcinoma
and squamous cell lung cancer).
Conclusions: Our work provides a detailed overview of the mutational characteristics in each of nine major cancers
and highlights that the mutational signature profile is representative of each cancer.
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Somatic mutations are a major cause of cancer develop-
ment [1]. Recent advances in next-generation sequen-
cing (NGS) technologies have revealed that hundreds to
thousands of somatic nonsynonymous mutations could
exist in a single cancer genome [2-7]. The causes and
forces that lead to these mutations remain largely un-
known. In cancer research, somatic mutations can be
categorized as driver mutations and passenger muta-
tions. Driver mutations are defined as those that confer* Correspondence: zhongming.zhao@vanderbilt.edu
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unless otherwise stated.growth advantages to tumor cells and are under positive
selection [8]. In contrast, passenger mutations do not
contribute to cancer development [8]. While selection
has been well considered as a mutational force that
operates within cancer genomes, a previous study has
shown that selection affects only a small amount of the
mutations and the mutation patterns are not signifi-
cantly biased by either positive or negative selection [9].
Recently, several pan-cancer genome studies have been
reported by The Cancer Genome Atlas (TCGA), aiming
to study simultaneously thousands of cancer genomes
across many cancer types [10-14]. Through these stud-
ies, a total of 21 mutational signatures were extracted
from 30 types of cancers, providing not only the land-
scape but also a dictionary of mutational signatures inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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previously recognized internal and external risk factors
involving DNA damage, such as environmental DNA-
damaging agents, tobacco carcinogens [15,16], radiation,
and chemicals, but also revealed novel mechanisms that
mark cancer genomes with specific mutational patterns
[2,17]. For example, the kataegis signature was found to
be highly correlated with a DNA repair process mediated
by the AID/APOBEC family proteins [18]. In addition to
mutagen-driven forces (e.g., tobacco smoking and sun
exposure), failures in DNA repair systems lead to a rapid
accumulation of somatic mutations in cancer genomes.
In fact, somatic mutations in each cancer genome could
reflect the lifetime interplay between DNA damage and
DNA repair processes in cancer patients [17,19]. To
date, the mechanisms discovered that could disrupt
DNA repair genes include somatic mutations [20], copy
number alterations [21], dysregulated gene expression
[22], and epigenetic changes [23]. For example, hyper-
methylation in the MLH1 gene, and correspondingly, its
decreased expression level, could result in microsatellite
instability (MSI) [24]. In summary, heterogeneous muta-
tional signatures and processes were highlighted as a
prevalent phenomenon in cancer [13], further complicat-
ing the studies of cancer somatic mutations.
While these pioneering studies have established the
first architecture of somatic mutation patterns in pan-
cancers, a detailed and deep exploration of mutational
profiles within and between cancer types has not yet
been performed. For example, how many heterogeneous
mutation forces directly affect each cancer type and each
single cancer genome? And, to what extent does each
process act to modulate and shape the mutational
spectrum we have observed in cancer genomes? Further-
more, while mutagen exposures, such as tobacco smok-
ing, drive specific mutation patterns that are detectable,
it has not yet been established whether DNA repair sys-
tems behave similarly on cancer genomes, e.g., form spe-
cific mutation patterns.
In this work, we implemented the Non-negative Matrix
Factorization (NMF) algorithm [18] to decompose and de-
tect somatic mutation signatures in nine major cancers.
Although some signatures have been previously reported,
our analysis reveals heretofore unrecognized features.
In contrast to pan-cancer signatures, we aim to study the
signatures in each cancer and to investigate intra- and
inter-cancer mutation signature profiles. First, our results
revealed 3-5 independent mutational signatures in each
cancer, implying that 3-5 primary mutational processes
are critical for tumorigenesis. Specifically, we identified
three mutagen-driven signatures, three DNA-repair re-
lated signatures, and one recurrent signature with C→T
mutations at non-CpG island (CGI) regions. Second, our
assessment of the mutagen-driven mutational loads (e.g.,the smoking related signature in smokers versus never-
smokers) in tumor genomes revealed correlations with the
clinical data and demonstrated intra-cancer heterogene-
ities of the same cancer type. Additionally, we observed
different combinatory patterns of mutation signatures in
each cancer type, highlighting the prevalent heterogene-
ities among different cancers. These results provide a de-




As summarized in Table 1, we collected somatic single nu-
cleotide variants (SNVs) in nine major cancers from sev-
eral large-scale NGS projects: breast cancer (BrCa_21 with
data from reference [18] and 507 TCGA BRCA [25]), 224
colon and rectal cancers (CRC) [26], 248 endometrial car-
cinomas (EC) [27], 290 glioblastoma (GBM) [23], 74 head
and neck squamous cell carcinomas (HNSCC) [6], 182
lung adenocarcinomas (LUAD) [15], 121 melanoma [28],
316 ovarian carcinomas (OvCa) [29], and 177 squamous
cell lung cancers (SQCC) [30]. Six of these cancer datasets
were from TCGA: BRCA, CRC, EC, GBM, OvCa, and
SQCC. For these, the glioblastoma mutation data was
downloaded recently (May 12, 2013) and the other five
cancers were downloaded using the data reported in the
original publications (Table 1). With the exception of the
21 breast cancer samples whose data was generated
through whole-genome sequencing (WGS), all the data in
the remaining samples was based on whole exome se-
quencing (WES). The downloaded mutation data was all
previously mapped to gene regions. Therefore, among
WES samples, the scale of the mutation numbers per sam-
ple is comparable to each other.
We download the Consensus CDS (CCDS) informa-
tion and the respective coding DNA sequences, CpG is-
land data, and human reference genome (hg18 and
hg19) from the UCSC Browser [31]. Gene expression
data was retrieved from the TCGA data portal [32]. The
POLE mutation data for CRC samples was downloaded
from the cBio Portal for Cancer Genomics [33]. The
POLE mutation data for EC was extracted using the “In-
tegrative Cluster” information provided by the original
study [27]. The MSI status data for both CRC [26] and
EC [27] were downloaded from the original work.
Mutation signature detection
Non-negative Matrix Factorization (NMF) has been fre-
quently applied in detecting mutation signatures from
somatic mutation data. A detailed description of NMF
can be found in a previous study [18] and in Additional
file 1: Text S1. Briefly, given a mutation matrix M in
which rows represent the 96 available trinucleotides and
columns represent tumor samples, NMF factorizesM into
Table 1 Description of the mutation datasets
Dataset Cancer type Sequencing platform # samples # SNVs Pub. year Reference
HNSCC Head and neck squamous cell carcinoma WES 74 9398 2011 Stransky et al. [6]
LUAD Lung adenocarcinoma WES, WGS 182 62,767 2012 Imielinski et al. [15]
Melanoma Melanoma WES 121 220,430 2012 Hodis et al. [28]
TCGA_BRCA Breast tumors WES 507 31,538 2012 TCGA [25]
TCGA_CRC Colon and rectal cancer WES 224 90,059 2012 TCGA [26]
TCGA_EC Endometrial carcinoma WES 248 181,815 2013 TCGA [27]
TCGA_GBM Glioblastoma WES 290 20,949 2008 TCGA [23]
TCGA_OvCa Ovarian carcinoma WES 316 18,296 2011 TCGA [29]
TCGA_SQCC Squamous cell lung cancer WES 177 64,339 2012 TCGA [30]
SNVs: single nucleotide variants.
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where r is the factorization rank corresponding to the
number of mutational signatures to be detected, and N is
the total number of samples. r is determined by evaluating
the cophenetic correlation and sparseness. The matrix
W96×r contains r columns, each of which represents a
mutational signature. We assume that an observed
signature in a cancer genome is produced by a major
mutational process. The matrix Hr×N contains N columns,
where Hr×j = [βi,j]
T, i = 1:r and j = 1:N. The coefficient βi,j
represents the load of the ith signature on the fraction of
mutations in the jth sample.
Results
Each cancer has distinct and distinguishable
mutational signatures
Although pan-cancer analyses have been comprehen-
sively performed in recent studies, cancer type specific
mutation signatures were only explicitly examined in
breast cancer. Nik-Zainal et al. [18] and Fischer et al.
[34] proposed that breast cancer genomes had 5 bio-
logically distinct signatures. One of these signatures is
called kataegis and is a phenomenon of regional hyper-
mutation in cancer genomes. We first replicated the re-
sults of this earlier work using the same WGS dataset of
21 samples (denoted as BrCa_21). With this proof of the
concept, we then applied the approach to each of the
nine cancers, including a WES dataset of 507 TCGA
breast cancer samples (Table 1). The overall results and
performance assessment in each cancer using different r
are provided in Additional file 2: Table S1.
In previous pan-cancer studies, Alexandrov et al. [10]
pooled all 30 cancers and identified 21 signatures. Here,
we focused on the signature profile in each cancer type
and applied NMF independently in each cancer. For bet-
ter comparison, we used the same color scheme and plot
style as in the original work [18] and in Alexandrov
et al. [10]. As shown in Figure 1, the NMF method
achieved the best fitting of the mutation matrices withfour signatures in most of the nine cancers, with a nar-
row range of three to five. HNSCC, GBM, and OvCa
were found to have three signatures each. EC and SQCC
had five signatures each. All the remaining cancers had
four signatures. Thus, complex but limited patterns of
mutational signatures are detectable in most cancer ge-
nomes. Assuming each signature is primarily driven by a
major process, somatic mutations would be the outcome
of multiple independent biological processes in cancer
genomes. No single process can explain all somatic muta-
tions in any cancer. Furthermore, while several signatures
are recurrent in multiple cancers (see below), inter-cancer
differences are remarkable in their combination of mul-
tiple signatures for each cancer type. Table 2 summarizes
the mutational signature profile for each cancer.
Features of representative signatures
The S-signature: smoking-related signature (mutagen-driven)
Tobacco and sun exposure are well-known mutagen
sources that cause DNA damage and have specific muta-
tion patterns. The fingerprint mutation due to tobacco ex-
posure is a C→A transversion, which is predominantly
found in smokers [15]. In both LUAD and SQCC, the
C→A mutations appeared as an independent signature
(LUAD signature #2 and TCGA_SQCC signature #3, the
cyan bars, Figure 1). We denoted it as the S-signature,
reflecting the effect of smoking. Notably, the S-signature
has moderate coefficients for all 16 trinucleotides related
to C→A, implying that among the tobacco-driven C→A
mutations, there is no particularly favorable neighboring
sequence context. It is worth noting that, in HNSCC,
we also observed the S-signature (HNSCC signature #3,
Figure 1), consistent with the observation that many
HNSCC patients have a history of tobacco smoking.
The UVA- and UVB-signatures: sun-exposure related
signatures (mutagen-driven)
In nature, sun exposure leads to DNA damage through
three major types of UV light. UVC is largely blocked by
Figure 1 Mutational signatures in 9 types of cancer. X-axis denotes the 96 trinucleotide substitutions. Y-axis denotes the relative coefficient of
each substitution to the corresponding signature (the matrix W96×r, see the main text). For each cancer, the plot in each panel represents one
detected signature. HNSCC: head and neck squamous cell carcinoma. LUAD: lung adenocarcinoma. TCGA_BRCA: the breast cancer data from
TCGA. TCGA_CRC: colon and rectal cancer. TCGA_EC: endometrial carcinoma. TCGA_GBM: glioblastoma. TCGA_OvCa: ovarian carcinoma.
TCGA_SQCC: squamous cell lung cancer.
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are the main sources of UV light-produced DNA dam-
age. UVA primarily induces C→A [28,35], and UVB in-
duces C→ T [28] mutations; however, recent studies
found that UVA might lead to C→T mutations as well
[36,37]. In melanoma, the first signature is indicative of
UVA exposure, as it features C→A mutations (melan-















Details of datasets are provided in Table 1. CGI: CpG island.signature), the fourth signature features C→ T (melan-
oma #4, the red bars, Figure 1), likely due to UVB con-
tribution (denoted as UVB-signature). DNA damage due
to UV exposure leads to covalent bonds between two ad-
jacent pyrimidines (Py) [38]; therefore, mutations at Cs
created by UV light usually occur in the context of
bipyrimidines [19]. In our results, both UVA- and UVB-
signatures (melanoma #1 and #4) favored pyrimidines atSignature
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in the UVA-signature and C(C→ T)X and T(C→ T)X
in the UVB-signatures had relatively high coefficients.
This result not only supported that those signatures
were UV related, but also confirmed a prevailing Py-C
mutation pattern led by UV exposure.
The K-(kataegis) signature: C→ T and C→ G in a
trinucleotide, TCX
In the previous investigation by Nik-Zainal et al. [18],
C→T mutations in the TpCpX trinucleotide context
clustered within genomic regions of several megabases (i.e.,
in cis-fashion) and tended to occur with a special strand
preference. For example, the C→T mutations occur con-
tinuously on one strand and then jump to the reverse
strand (G→A); however, they do not mix on the same
strand. The transversion of C→G enriched at the TpC di-
nucleotide context has also been observed previously in
lung and ovarian cancers [2]. In our work, we confirmed
the kataegis signature (abbreviated as the K-signature in
Figure 1) in breast cancer (TCGA_BRCA signature #1,
Figure 1), endometrial carcinoma (TCGA_EC #5), head
and neck squamous cell carcinoma (HNSCC #1), lung
adenocarcinoma (LUAD #3), and squamous cell lung can-
cer (TCGA_SQCC #4), featured with C→T and C→G
mutations in the context of the TCX trinucleotide. The
C→T mutations in the TpC dinucleotide context related
to the kataegis signature have been associated with the
AID/APOBEC mediated DNA repair system [18,22,39,40].
We also systematically examined all 11 members of the
APOBEC family using the TCGA RNA sequencing (RNA-
seq) data (Additional file 3: Table S2 and Additional file 4:
Table S3). Positive correlations were observed between the
K-signature related mutation burden and increased expres-
sion of APOBEC3B or APOBEC3A (see Additional file 5:
Figure S1), which is consistent with previous reports [40].
The L-(low level MSI or MSS) signature: T(C→ A)T and T
(C→ T)G, and the H-(high level MSI) signature: C(C→ A)X
and G(C→ T)X
In colon and rectal cancer and endometrial carcinoma,
we observed two shared signatures. The first signature
features T(C→A)T and T(C→ T)G (TCGA_CRC #4
and TCGA_EC #3, Figure 1). This signature was found
with high coefficients (i.e., more importance) in samples
with low levels of a microsatellite instable (MSI-L) status
(green dots in Figure 2A) or a microsatellite-stable
(MSS) status (red dots in Figure 2A) in both CRC and
EC samples. We thus denoted it as the L-signature for
low-level MSI or MSS status. The second signature con-
tains C(C→A)X and G(C→ T)X (TCGA_CRC #1 and
TCGA_EC #2, Figure 1) and was found to play more
roles in samples with mutant POLE and high levels of
MSI status (MSI-H) (Figure 2C and D, blue dots). Wedenote this signature as the H-signature for high-level
MSI status. These results indicated that the L- and H-
signatures were likely associated with the microsatellite
status and deficiencies in the DNA repair gene POLE.
Considering the relationship between L- or H-signatures
and microsatellite status, we explored their correlations in
the context of the MLH1 expression level, which was re-
ported to cause microsatellite instability. As expected,
CRC samples with high relative H-signature coefficients
tended to distribute both toward a low MLH1 expression
and have a MSI-H status (blue vertical lines in Figure 3).
In contrast, the seven CRC samples with the highest coef-
ficients had no obvious correlation with MLH1 expression
levels. A similar trend was observed in endometrial carcin-
oma samples: samples with low MLH1 expression tended
to have high H-signature coefficients. For the L-signature,
EC samples with high coefficients seemed to be randomly
distributed in samples with low MLH1 expression levels. In
summary, the H-signature with C(C→A)X and G(C→T)
X tended to occur in MSI-H samples with a low expression
of MLH1, while the L-signature with T(C→A)T and T
(C→A)G occurred mainly in MSS or MSI-L samples and
had no apparent link withMLH1 gene expression.The non-CGI-signature: C→ T in CG dinucleotides in
non-CpG island (CGI) regions
We found a signature characterized by C→T in the
context of CG dinucleotides in seven of the nine can-
cers: BRCA, CRC, EC, GBM, HNSCC, LUAD, and
OvCa. The signature was not detected in melanoma.
The mutation patterns in this signature resemble the
age-related signatures discovered in Alexandrov et al.
[10] (called “signatures 1A/1B”).
The mutation rate at nucleotide C in the methylated
CpG dinucleotide context has been found at 10- to 50-
fold higher levels than that of other sites [41]. CpG dinu-
cleotides often cluster in the genome and form CGIs,
even though they occur at only approximately 25% of
the expected frequency in the human genome [42]. To
explore the correlation between this signature and the
features of CGIs, we applied NMF to specifically exam-
ine X(C→T)G mutations that were located inside and
outside of CGIs, respectively, in the seven cancers
in which the signature was detected. As shown in
Additional file 6: Figure S2, by comparing the results
obtained with or without X(C→T)G mutations in
non-CGI regions, we found that the signature was sub-
stantially diminished, or even barely detectable, after ex-
cluding X(C→T)G mutations in non-CGI regions in all
seven cancers. This finding indicated that this signature
was mainly formed by X(C→T)G mutations in non-
CGI regions. Accordingly, we termed it the non-CGI-
signature.


































































































































Figure 2 Distribution of the L- and H-signatures in colon and rectal cancer (TCGA_CRC) and endometrial carcinoma (TCGA_EC). X-axis:
sample indexes. Y-axis: relative coefficient of the signature. In the L-signature, samples with a microsatellite stable status (MSS, red dots) or low
levels of a microsatellite instable status (MSI-L, green dots) have high coefficients in both colon and rectal cancer (A) and endometrial carcinoma
samples (B). In the H-signature, samples with high levels of MSI (MSI-H, blue dots) have high coefficient in both colon and rectal cancer (C) and
endometrial carcinoma samples (D). Samples with POLE mutations were denoted by large circles.
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concordant with and indicative of clinical data
We explored the biological and clinical implications of
the observed mutational signatures. We hypothesized
that if a signature were indeed generated by a mutagen
exposure process, the mutation load that it forms as a
fraction of the overall mutation load of the sample
would be correlated with the patient’s smoking or sun
exposure history. Here, the signature-specific mutation
load is measured by its relative coefficient, calculated by
the actual coefficient divided by the sum of all coeffi-
cients in each sample such that the sum of all relative
coefficients per sample equals 1. Among the four can-
cers with mutagen-driven signatures (HNSCC, LUAD,
melanoma, and SQCC, Table 2), the LUAD and HNSCC
datasets provide smoking exposure information. The
LUAD samples were categorized into four groups ac-
cording to the number of consumed packs of cigaretteper year: heavy smoker, light smoker, never smoker, and
unknown [15]. By overlaying the smoking status to the
distribution of the signature mutation load in each
sample, we found the S-signature contributed to heavy,
light, and never smokers with a steadily decreasing
scale (Figure 4A). A similar trend was observed in
HNSCC samples (Figure 4B). Based on the clinical data,
we denoted HNSCC never smokers as those that con-
sume zero packs of cigarettes per year; all other sam-
ples were smokers [6]. The relative coefficients of the
S-signature (HNSCC #3) were significantly lower in
HNSCC never smokers compared to HNSCC smokers
(p = 9.49 × 10-6, t-test). Furthermore, tumors with heavy
loads of the S-signature (i.e., those with the S-signature
coefficient ranked between 1-50% in a decreasing order)
were associated with significantly more cigarette packs per
year than those with light loads (ranked between 51-100%)
(p = 0.003, t-test).
Figure 3 Coefficient distribution of the L- and H-signatures in samples ordered by MLH1 gene expression level. Top panel: MLH1 gene
expression relative to the house-keeping gene, TBP, sorted. Middle panel: the H-signature coefficients in each sample. Samples are listed in the
same order as on the top panel. Samples with a high level of MSI are labeled in blue. Bottom panel: the L-signature coefficients in each sample.
Samples are in the same order as on the top panel. The figure shows that the samples with a high coefficient of signature #1 had low expression
values of MLH1 gene.
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exposed or non-sun-exposed areas, we performed a similar
analysis to investigate the correlation between UV-related
signatures and the anatomical origins of different tumors.
As shown in Additional file 7: Figure S3, acral melanomas
(that arise on the hands and feet) tend to have a smaller
load of UVA-/UVB-signatures compared to those from
body skin. These observations collectively indicate that the
mutational signatures we observed provide implications
for their biological mechanisms and clinical histories. In
addition, patients with the same cancer type, and even the
same subtype (e.g., smokers), have different load of each
signature, implying intra-cancer differences being prevalent.
Inter-cancer combinatory patterns of mutational
signatures are distinguishable between cancer types
Based on the mutational signatures and their potential bio-
logical implications above, we next examined the combina-
torial patterns of signatures for each cancer. As shown in
Table 2, no cancer types share the same combination of sig-
natures (i.e., signature profile), even though several signa-
tures are present in two or multiple cancers. For example,
three cancers have both mutagen-driven and DNA repair
related processes: HNSCC, LUAD, and SQCC, all of which
have the smoking related S-signature and the APOBEC re-
lated K-signature. Of note, even the two types of lung can-
cer, LUAD and SQCC, have distinct mutation patterns.
LUAD has the age-related non-CGI-signature but SQCCdoes not, further demonstrating the extensive heteroge-
neous mutations and processes underlying each cancer. A
similar pattern was also observed in ref. [10], where lung
SQCC samples were found to have 3 signatures (APOBEC,
smoking, and signature 5 in [10]) plus an unknown signa-
ture named “other”, lung small cell samples were found
with 2 (smoking and signature 15 in [10]), and LUAD were
found with 4 (age, APOBEC, smoking, and signature 5 in
[10]) plus the “other” signature. Three cancers have only
DNA repair related processes: BRCA, CRC, and EC,
none of which have an explicit mutagen-driven related
process. One cancer, melanoma, has only mutagen-driven
signatures: the UVA- and UVB-signatures. The remaining
two cancers, GBM and OvCa, do not have signatures
confidently linking to either a mutagen-driven or DNA
repair related process. Even though some cancers have
private signatures (i.e., not observed in any other
cancers), such as TCGA_GBM #1 and TCGA_SQCC #1
(Figure 1), it is actually not the private signatures but
rather the combination of mutation patterns that dis-
tinguish these cancers. In summary, both common and
unique signatures exist among the nine cancers that we
examined, yet the combinations of mutational signatures
are representative and distinct in each cancer.
Discussion
We systematically analyzed mutational signatures among
nine major types of cancer, each of which displayed
Figure 4 Contribution of the S-signature (represented by the vertical blue bars) to each lung adenocarcinoma (LUAD) sample (A) and
to the head and neck squamous cell carcinoma (HNSCC) sample (B), measured by the relative coefficients. The relative coefficients were
computed based on the true coefficients such that the sum of the relative coefficients for all signatures in each sample equals to 1. Blue: the
S-signature. Black: the K-signature. Red: the non-CGI-signature. Yellow: the random signature.
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nisms. Our results revealed that the number of muta-
tional processes within each type of cancer is in a small
range, i.e., 3-5, with no single process being qualified to
explain the overall somatic mutations in any individual
cancer type. Both intra-cancer and inter-cancer hetero-
geneity is well recognized and represented in the muta-
tional signatures we identified. In cancers with known or
traceable mutagenic sources, such as lung cancers and
melanoma, signatures contributed by DNA damage
seem to be the major mutation processes. On the con-
trary, several other cancers, such as BRCA, CRC, and
EC, have mutational spectra that are shaped by DNA re-
pair systems, such as somatic mutations in DNA repair
genes or abnormal gene expression.
Although many of these signatures were reported right
after we completed our analyses, our work focused on
the mutational signatures within each single cancer typeand studied in more detail each signature, providing the
following new insights into cancer research. First, while
heterogeneity has been highly appreciated in recent in-
vestigations, only 3-5 independent signatures were found
in each of the nine cancers we examined, implying that
a small number of primary mutational processes could
mainly shape a cancer genome. This is an estimation
based on the current data, and in a recent pan-cancer
analysis [10], the number of processes was reported to
be between 2 and 6 in each of the 30 cancers. There are
several reasons for the differences. The previous work
did not count the “other” signature. For example, both
GBM and OvCa were denoted to have three signatures
in the present work but two signatures plus the “other”
signature in Alexandrov et al. [10]. Sample difference is
another major reason for the differences between our
work and the previous work. Most of the cancers har-
boring 6 signatures are not included in our work. Outlier
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tures. For example, we observed the UVB-signature in
SQCC unexpectedly. However, by exploring the load of
each signature in each sample, one SQCC sample con-
tributed predominantly to the UVB-signature of SQCC
(Additional file 8: Figure S4). After excluding this outlier
sample, four major mutation signatures were identified
for SQCC, indicating that the UVB-signature we ob-
served is not a prevalent signature in SQCC.
Second, the mutation load enforced by each signature
and its underlying process are detectable. In particular,
the mutation load resulting from mutagen related signa-
tures, as linked to the mutagen driven processes, is indi-
cative of exposure history and clinical data. For example,
based on the mutation load of the S-signature, the
LUAD samples shown in Figure 4 with an unknown
smoking status are implied to be heavy or light smokers
rather than never smokers.
Third, both intra- and inter-cancer differences are in-
dicative from the mutation signature profiles. These dif-
ferences are well-represented by the mutation load in
each single cancer samples with the same cancer type or
subtype, as well as, by the combinatorial pattern of mul-
tiple mutation signatures in each cancer type.
This work has the following limitations. First, there
are still several signatures whose biological mechanisms
remain unclear, including several private signatures that
were uniquely observed in only one specific type of can-
cer. For example, the first signature in EC (TCGA_
EC #1) features T→ C mutations and the first signature
in SQCC (TCGA_SQCC #1) has several C→A muta-
tions (Figure 1). Future work is needed to interpret these
signatures, perhaps with the incorporation of high-
throughput genetic and genomic data from multiple do-
mains as well as whole genome sequencing data. Second,
the number of mutational processes selected for each
cancer was determined by the cophenetic correlation
and sparseness calculations but may not always be the
best fit within biological systems. For most cancers, a
single best model can be accomplished upon the detec-
tion of the number of applicable mutational processes.
However, a manual check is necessary for performance
optimization. For example, a previous study discovered 5
mutational signatures in 21 breast cancer samples [18].
In our work, we found 4 signatures using TCGA_BRCA
samples. Our further inspection of those models with 4
signatures and 5 signatures concluded that 4 is appropri-
ate for the TCGA_BRCA data because when using 5 sig-
natures, the fifth signature stood out as a duplicate
random mutational process.
Conclusions
In this study, we implemented the NMF method to dis-
sect the mutational profiles of nine major cancers. Ourresults revealed 3-5 independent mutational signatures
in each cancer, implying heterogeneous mutational pro-
cesses prevalently exist in cancer genomes to modulate
the somatic mutational spectra. Both mutagen exposure
(e.g., tobacco and sun) and changes in DNA repair sys-
tems are capable of producing DNA damage that results
in major mutational signatures in cancer genomes. We re-
vealed features for several important signatures. Samples
of the same cancer type were found with markedly different
load of the same signatures, e.g., the S-signature in smokers
versus never smokers, indicating a prevalent heterogeneity
within (intra-) cancer types. In contrast, samples of different
cancer types showed different profiles of mutational signa-
tures, highlighting the heterogeneity among (inter-) differ-
ent cancer types. This work provides a unique overview of
somatic mutations in each of the nine cancers.
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